AGEN Stock Analysis for Money Stockers
Introduction
We turn our attention to Agenus Inc. (AGEN), situated in the Biotechnology industry within the Healthcare sector. Trading activity on 2025-05-30 00:00:00 placed the stock price at $3.43, reflecting a robust technical setup, holding above primary moving averages. Staying above these critical SMAs generally signifies positive market sentiment and upward momentum. Boasting a market cap around $163.13 M, AGEN represents a significant player in its field.
This report offers a multi-faceted analysis of Agenus Inc. (AGEN), integrating technical signals, fundamental data, and forward-looking forecasts. The aim is to provide investors with a balanced perspective on the stock’s current market standing, potential risks (see Risk Factors), and future performance outlook.
Business Overview
Operationally, the company is engaged in: Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body’s immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a sapo…
Metrics Summary
This snapshot summarizes AGEN’s current position. Currently priced at $3.43, AGEN has a model-based 1-year forecast around $2.12 (a -38.1% potential change). The technical picture shows a Neutral-Bullish bias (Above SMA 50, Above SMA 200). Price swing intensity is measured by volatility at 92.7%. Further details on the technical and fundamental aspects are explored below.
Detailed Forecast Table
Here’s the breakdown of the month forecast for AGEN ($0.00 to $41.10 overall range). The table shows projected price bands, potential ROI against the current price, and the resulting model signal per period.
Over the forecast horizon (2025-05 to 2026-05), AGEN’s price is projected by the model to fluctuate between approximately $0.00 and $41.10.
The projected price range remains relatively consistent (from $3.36 – $3.36 to $0.00 – $21.86), implying stable forecast uncertainty.
| Month (Period) | Min. Price | Avg. Price | Max. Price | Potential ROI vs Current ($3.43) | Model Signal |
|---|---|---|---|---|---|
| 2025-05 | $3.36 | $3.36 | $3.36 | ▼ -2.1% | Hold/Neutral |
| 2025-06 | $0.00 | $4.98 | $26.67 | ▲ 45.2% | Consider Buy |
| 2025-07 | $0.00 | $4.99 | $41.10 | ▲ 45.4% | Consider Buy |
| 2025-08 | $0.00 | $4.75 | $29.66 | ▲ 38.5% | Consider Buy |
| 2025-09 | $0.00 | $4.38 | $27.87 | ▲ 27.6% | Consider Buy |
| 2025-10 | $0.00 | $3.87 | $27.35 | ▲ 13.0% | Consider Buy |
| 2025-11 | $0.00 | $3.31 | $29.65 | ▼ -3.5% | Consider Short |
| 2025-12 | $0.00 | $2.95 | $32.72 | ▼ -14.1% | Consider Short |
| 2026-01 | $0.00 | $2.74 | $32.72 | ▼ -20.1% | Consider Short |
| 2026-02 | $0.00 | $2.49 | $34.38 | ▼ -27.5% | Consider Short |
| 2026-03 | $0.00 | $2.41 | $26.92 | ▼ -29.7% | Consider Short |
| 2026-04 | $0.00 | $2.27 | $26.39 | ▼ -33.7% | Consider Short |
| 2026-05 | $0.00 | $2.12 | $21.86 | ▼ -38.1% | Consider Short |
Forecasts are model-based estimates, inherently uncertain, and subject to change based on evolving data and market conditions. They do not guarantee future prices.
Total Valuation
Total valuation metrics offer a broader perspective beyond market capitalization. Looking beyond market cap, the Enterprise Value (EV), currently N/A, offers a broader view of AGEN’s value by including debt and cash. Relating this EV to performance, the EV/Revenue multiple stands at 2.57x, and the EV/EBITDA multiple is -2.79x, gauging value against sales and core operational earnings respectively. These ratios help assess the company’s valuation relative to its sales and operating earnings. Key upcoming dates include the next earnings announcement (Est: 2025-05-12) and the ex-dividend date (N/A).
| Market Cap | $163.13 M |
| Enterprise Value | $236.68 M |
| EV/Revenue (TTM) | 2.57x |
| EV/EBITDA (TTM) | -2.79x |
| Next Earnings Date | 2025-05-12 |
Profitability Growth
This section examines AGEN’s ability to generate profit and expand its business. Profitability is reflected in margins: Gross (-34.28%), Operating (-55.31%), and Net (-191.50%). The company’s recent growth trajectory shows Revenue up -14.10% and Earnings up N/A YoY. Evaluating these margins and growth rates against historical performance 📜 and industry competitors 👥 provides crucial context. These are key indicators of financial performance and future potential.
| Profit Margin (TTM) | -191.50% |
| Operating Margin (TTM) | -55.31% |
| Gross Margin (TTM) | -34.28% |
| EBITDA Margin (TTM) | -92.12% |
| Revenue (TTM) | $99.52 M |
| Revenue Growth (YoY) | -14.10% |
| Gross Profit (TTM) | $-34.12 M |
| EBITDA (TTM) | $-91.69 M |
| Net Income (TTM) | $-190.81 M |
Analyst Insights
Here’s the consensus from Wall Street analysts on AGEN. The average recommendation is ‘Buy’. 4 analyst(s) contributed to this consensus view. Targets average $11.50 (within a range of $6.00 – $25.00). Based on the mean target ($11.50), this implies a potential upside of ~235.3% from the current price ($3.43). This reflects overall analyst sentiment on the stock’s outlook.
Technical Analysis Summary
This technical overview for AGEN (as of 2025-05-30 00:00:00) covers essential trend, momentum, and volatility indicators. Charts offer more detail, but this summarizes the key signals.
- Trend: Bullish Trend Confirmation, as price ($3.43) holds above both the key 50-day and 200-day SMAs, indicating positive momentum across timeframes.
- Momentum (RSI): ● 48.7 (Neutral), indicating balanced momentum.
Moving Average Details
Technical analysis uses past price and volume data to identify potential future trends but offers no guarantees. Combine with fundamental analysis and risk management.
Short Selling Info
Short selling data provides a measure of negative sentiment or bets against AGEN. Key short interest indicators include Short % of Float (15.04%) and the Short Ratio (4.20x). The current level is considered high. This implies notable bearish sentiment and suggests increased short squeeze potential. The low Days to Cover (4.20x) indicates shorts could cover relatively quickly, potentially limiting squeeze duration.
| Shares Short | $4 M |
| Short Ratio (Days To Cover) | 4.20x |
| Short % of Float | 15.04% |
| Shares Short (Prior Month) | $4 M |
| Short Date | 2025-05-15 |
Stock Price Statistics
This section summarizes AGEN’s stock price characteristics, including its sensitivity to market movements, historical trading range, recent price fluctuation intensity, and typical trading volume. Key price behavior metrics include Beta (1.43x), the 52-week trading range ($1.38 – $18.74), recent short-term volatility (92.7%), and average trading liquidity (3m Avg Vol: N/A). Beta (1.43x) suggests the stock is more volatile than the overall market. The recent volatility (92.7%) is high, indicating significant price swings.
| 52 Week High | $18.74 |
| 52 Week Low | $1.38 |
| 50 Day MA | $2.91 |
| 200 Day MA | $3.54 |
| Beta | 1.43x |
| Volatility (30d Ann.) | 92.7% 📉 |
Conclusion Outlook
Short-Term Technical Snapshot
- ▲Overall Technical Sentiment: Neutral-Bullish
- ▲Price Trend vs MAs: bullish (above SMA50/200)
- ●Momentum (RSI): Neutral (48.7)
- 📊Support / Resistance (30d): ~$2.70 / ~$4.06
Longer-Term Fundamental & Forecast Outlook
- ▼1-Year Avg. Forecast: ~-38.1% avg. change to ≈$2.12
- ●Fundamental Health: Assessment Incomplete (ROE: N/A, D/E: N/A)
- ●Valuation Snapshot: Appears Moderate (Fwd P/E: -0.61x)
- ●Recent Growth (YoY): N/A (Rev: -14.10%, Earn: N/A)
- ▲Analyst Consensus: Buy (Target: $11.50)
Overall Assessment & Outlook
Synthesizing the data, AGEN currently shows Neutral-Bullish technicals coupled with moderate fundamentals. The current valuation is assessed as Appears Moderate (Fwd P/E: -0.61x). Looking out one year, the forecast implies potential downside (-38.1%) with an average target near ≈$2.12. Careful consideration of these points relative to their personal risk tolerance and investment timeline.
Note: This report combines model projections and public data for educational use. It is not investment advice. Market conditions change rapidly. Always conduct thorough independent research and consult a qualified financial advisor before making investment decisions.
Risk Factors
Potential investors in AGEN should be aware of several risk factors. The following list highlights key considerations based on data and market dynamics, but may not include all possible risks.
- ⚠️ High Volatility: Recent annualized volatility (92.7%) suggests significant price swings.
- ⚠️ Overall market fluctuations can impact the stock.
- ⚠️ Factors specific to the Biotechnology industry or Healthcare sector can affect performance.
- ⚠️ Changes in macroeconomic conditions (interest rates, inflation) pose risks.
- ⚠️ Unforeseen company events or news can impact the price.